FibroBiologics (FBLG) Net Equity Issued and Repurchased (2024 - 2026)
FibroBiologics (FBLG) posted quarterly Net Equity Issued and Repurchased of $2.9 million for Q2 2026, up 305.38% on a QoQ basis from $706000.0 in Q1 2026.
FibroBiologics (FBLG) Net Equity Issued and Repurchased (2024 - 2026) Analysis & Trends
FibroBiologics has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at $2.9 million in Q2 2026.
- Net Equity Issued and Repurchased for Q2 2026 came in at $2.9 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2026 was $3.6 million (down 23.89% YoY), and the FY2025 annual result was $6.6 million, down 12.22% from the prior year.
- Net Equity Issued and Repurchased improved to $2.9 million in Q2 2026, from $706000.0 in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $4.6 million in Q3 2024 and troughed at $19000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | FibroBiologics | 8.97 Mn | 8.97 Mn | - | 2.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.86 Mn |
| Jun 30, 2026 | 2.86 Mn |
| Mar 31, 2026 | 706,000.00 |
| Mar 31, 2026 | 706,000.00 |
| Dec 31, 2024 | 45,000.00 |
| Dec 31, 2024 | 45,000.00 |
| Sep 30, 2024 | 4.64 Mn |
| Sep 30, 2024 | 4.64 Mn |
| Jun 30, 2024 | 19,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Mar 31, 2024 | 2.80 Mn |
| Mar 31, 2024 | 2.80 Mn |